Looking for a top portable Bluetooth speaker? We've tested a bunch of them, and these are our current favorites. Executive Editor David Carnoy has been a leading member of CNET's Reviews team ...

Portable Bluetooth speakers ... be enough to feed a Raspberry Pi 4, but plenty for an Arduino Nano. So far functionality for three of the four buttons on this speaker has been preserved: power ...

At the beach, the park, or wherever else your adventures take you, having a portable Bluetooth speaker allows you to take the music wherever you go. There are many portable Bluetooth speakers out ...

Making your own that checks off all those boxes can be. [Peter Clough] took the latter route and built a small Bluetooth speaker with an LED visualization display that he calls Magic Box.

Ty Pendlebury is a journalism graduate of RMIT Melbourne, and has worked at CNET since 2006. He lives in New York City where he writes about streaming and home audio. Expertise Ty has worked for ...

“Given there is still significant development risk and expected time to top-line contribution is still ~4 years out, we make no changes to our Market Perform rating at this time,” said the not ...

The important circuits using diodes are rectifiers, clippers, clampers, and peak value storage devices. The circuit for a full-wave rectifier, or absolute value circuit or modulus value circuit is ...

(Reuters) -Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the ...

The federal agency's consumer price index for March 2024 saw a 2.9 per cent increase compared ... such as air transportation, was up by 4.5 per cent. But goods — the items consumers and ...

Vertex will pay $65 a share in cash for Alpine, the companies said Wednesday in a statement, 67% more than Alpine’s closing price Tuesday of $38.94. Alpine shares rose as much as 37% Thursday ...

Boston-based Vertex said late Wednesday it was acquiring Alpine for $65 a share in cash, or $4.9 billion, giving it access to the company’s product candidate for chronic kidney disease.